 Subjects will be enrolled in a targeted 1:1 stratification ratio into 1 of 2 chemotherapy treatment arms at the investigators discretion: carboplatin plus paclitaxel or carboplatin plus Pegylated Liposomal Doxorubicin PLD, and then randomized in a 2:1 ratio to receive weekly farletuzumab 5 mgkg or placebo ie, Test Article. All subjects will receive a loading dose for the first 2 weeks of 10 mgkg Test Article farletuzumab or placebo. Subjects will be stratified at randomization by individual chemotherapy treatment regimen targeted 1:1 ratio and platinum-free interval following first-line therapy 6 to 12 months vs greater than 12 to 36 months. 